Our network meta-analysis showed that in cases of dysmenorrhea, GnRH agonists supplemented with CHCs after 3 months, in cases of dyspareunia, CHCs alone, and in cases of overall pelvic pain, CHCs or progestins combined with aromatase inhibitors should be the first choice for the management of endometriosis-related pain. This evidence concerns the gene GNRH1 and endometriosis.